NCT02982915已完成1 期
Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 12
- 主要终点
- The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:
研究概览
简要总结
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
详细描述
A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of Lomecel-B (Formerly LMSCs). This will be followed by a double-blinded, randomized, placebo-controlled phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 65 Years 至 90 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •be willing and able to provide written informed consent and comply with all procedures required by the protocol.
- •be 65 - 90 years of age at the time of signing the Informed Consent Form.
- •have a diagnosis of Aging Frailty, with a score of 4 to 7 using the Canadian Frailty Scale.
- •have a six-minute walk test (6MWT) distance of 200m - 400m for each of 2 trials, and the 2 trials must be within 15% of each other.
- •have total bilirubin between 0.3 - 1.9 mg/dL.
排除标准
- •be unwilling or unable to perform any of the assessments required by the Protocol.
- •score ≤24 on the Mini Mental State Examination (MMSE).
- •have previously received current year's flu-vaccine.
- •have any contraindication to receiving a vaccine.
- •have a Hemoglobin A1c (HbA1c) level >9.0%.
- •be diagnosed with malignancy (subjects without a recurrence in the last 2.5 years will be allowed) except curatively-treated basal cell carcinoma, melanoma in situ, or cervical carcinoma.
- •have a condition that projected to limit the life-expectancy to ≤1 year.
- •have autoimmune disease (e.g., rheumatoid arthritis).
- •be using medication(s) known to alter immune response, e.g., high-dose corticosteroids.
- •have HIV, AIDS, or other immunodeficiency.
- •test positive for hepatitis B virus
- •If the subject tests positive for anti-HBc or anti-HBs, they must be receiving treatment for Hepatitis B virus prior to infusion and remain on treatment throughout the study.
- •test positive for viremic hepatitis C, HIV1, HIV2, or syphilis.
- •have a resting blood oxygen saturation of <93% (measured by pulse oximetry).
- •be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception.
- •have documented current substance and/or alcohol abuse.
- •have known allergies to latex or eggs.
- •have a known hypersensitivity to dimethyl sulfoxide (DMSO).
- •be an organ transplant recipient (other than corneal, bone, skin, ligament, or tendon transplant).
- •be actively listed (or expected to be listed) for transplant of any organ (other than corneal, bone, skin, ligament, or tendon transplant).
- •have any clinically important abnormal screening laboratory values, including but not limited to:
- •hemoglobin <10.0 g/dL.
- •white blood cell count < 2500/mm
- •platelets < 100,000/mm
- •prothrombin time/international normalized ratio (PT/INR) ˃ 1.5 not due to a reversible cause (i.e. Coumadin).
- •aspartate transaminase, alanine transaminase, or alkaline phosphatase ˃ 2 times upper limit of normal.
- •have a sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.
- •have any serious illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study, or that may compromise the validity of the study.
- •be currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that the subject actively participates in this trial.
结局指标
主要结局
The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:
时间窗: 30 days after infusion
* Is life-threatening (e.g., stroke or non-fatal pulmonary embolism). * Requires inpatient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity. * Results in death * Results in other clinically significant untoward laboratory test result(s) or medical condition(s), determined per Investigator's judgment.
The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays.
时间窗: Baseline Visit, Vaccination Visits, Weeks 1, 2, 4, Month 6 and Month 12 Follow-Up Visits.
Measurements of validated hemagglutination inhibition (HAI) assays at follow up visits.
次要结局
- Rate of decline in Aging Frailty status as assessed by the 6 minute walk test(Baseline, month 6 and month 12 after infusion)
- Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)(Baseline, month 6 and month 12 after infusion)
- Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test(Baseline, month 6 and month 12 after infusion)
- Rate of decline in Aging Frailty status as assessed by the Weight Loss(Baseline, month 6 and month 12 after infusion)
- Rate of decline in Aging Frailty status as assessed by the Handgrip Test(Baseline, month 6 and month 12 after infusion)
- Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:(Baseline, month 6 and month 12 after infusion)
- Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:(Baseline, month 6 and month 12 after infusion)
- Differences in rate of decline from Aging Frailty(Baseline, month 6 and month 12 after infusion)
- Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment(Baseline, month 6 and month 12 after infusion)
- PROMIS Short Form 20a questionnaire(Baseline, month 6 and month 12 after infusion)
- PROMIS Mobility questionnaire(Baseline, month 6 and month 12 after infusion)
- PROMIS Upper Extremity questionnaire(Baseline, month 6 and month 12 after infusion)
- Short Form 36 questionnaire(Baseline, month 6 and month 12 after infusion)
- IIEF questionnaire(Baseline, month 6 and month 12 after infusion)
- SQOL-F questionnaire(Baseline, month 6 and month 12 after infusion)
- Death from any cause(Within 12 months after infusion)
- Falls Efficacy Scale-International (FES-I)(Baseline, month 6 and month 12 after infusion)
研究者
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)ARDS, HumanCovid19NCT04629105Longeveron Inc.70
尚未招募
2 期
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)Moderate to Severe Rheumatoid ArthritisNCT06306339ImmuneMed, Inc.60
招募中
1 期
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological MalignanciesGynecological Malignant TumorSolid TumorNCT05803018Sichuan Baili Pharmaceutical Co., Ltd.38
已完成
1 期
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisPsoriasis VulgarisNCT00277225Bristol-Myers Squibb32
已完成
1 期
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)Healthy ParticipantsNCT05684289Bristol-Myers Squibb61